Semaglutide Weight Management and Cardiovascular Risk Reduction
Phase 2 trial for CagriSema in people with type 2 diabetes was
successfully completed in Q3 2022
Exploratory phase 2a trial of CagriSema in 92 patients with T2D
Cagrilintide 2.4 mg + semaglutide 2.4 mg
R
Cagrilintide 2.4 mg + placebo
1:1:1
Semaglutide 2.4 mg + placebo
Dose escalation Treatment maintenance Follow up
16 weeks
5 weeks
16 weeks
Objective:
• To compare the efficacy and safety of CagriSema vs its individual
components in patients with T2D
Primary endpoint:
Change from baseline to week 32 in HbA1c
Secondary endpoints:
•
•
•
Change from baseline to week 32 in body weight
Safety
CGM: Mean glucose levels, time in range
Inclusion criteria:
.
Type 2 diabetes
•
HbA1c 7.5-10.0%
•
Metformin +/- SGLT-2i
•
BMI ≥27 kg/m2
T2D: Type 2 diabetes; R: Randomisation; BMI: body mass index; CGM: Continuous glucose monitoring; SGLT-2i: Sodium/glucose co-transporter-2 inhibitors
Note: CagriSema is a fixed dose combination of injectable cagrilintide 2.4 mg and injectable semaglutide 2.4 mgView entire presentation